Clinical Research Directory

Patients inclusion criteria: 1. Age ≥ 12 years 2. Willing to provide written informed consent to this study (by parents or tutors if underage) 3. Must have clinical and pathologic evidence of native kidney or recurrent C3G/IC-MPGN, as evidenced by all of the following: 1. C3G or IC-MPGN confirmed by renal biopsy (native kidney or kidney graft), with at least 2+ staining for C3c. 2. Clinical evidence of C3G or IC-MPGN in the form of at least 1 g/day of proteinuria in a 24-hour urine collection without other concomitant causes. 3. C3G or IC-MPGN must be primary and not secondary to another condition (eg, infection, malignancy, monoclonal gammopathy, autoimmunity, chronic antibody-mediated rejection, chronic thrombotic microangiopathy, or a medication). 4\) The patient is planned to initiate pegcetacoplan therapy as part of routine clinical practice (The decision to initiate pegcetacoplan treatment has been made by the treating physician according to routine clinical practice, independently of study participation). Patients exclusion criteria: 1. Inability to understand the potential risks and benefits of the study 2. Legal incapacity; 3. Patients treated with any anti-complement therapy within one month prior to baseline sample collection Healthy volunteers Inclusion criteria: * Male and female age \> 18 years; * Availability of written informed consent for biobank sample storage and use Healthy volunteers exclusion criteria: * History of renal diseases, autoimmune or coagulation disorders, diabetes mellitus, current allergies * Participants who have taken antibiotics, anti-inflammatory drugs, or antihistamines within the past 7 days